

PRESS RELEASE

Cellestis: 2014 financial results

March 4, 2015 – Paris (France) – Cellestis SA (Alternext: ALCLS) publishes its consolidated financial statements for 2014, as approved by the Board of Directors at their meeting on March 3, 2015.

- Total revenues and other income amounted to €26.4 M. This is mainly due to the collaboration agreements signed with Servier and Pfizer.
- Net loss for the period is €-0.972 M, including a loss of €2.8 M for the Tools and Services segment which operations were sold or terminated in 2014.
- As of December 31, 2014, shareholders' equity was €59.5 M, and cash and cash equivalents were €112.3 M.
- The accounts for the year ended December 31, 2014, have been audited. The audit reports are being prepared.

Consolidated financial statements

	Year Ended December 31,	
	2013	2014
	€ in thousands	
Revenues and other income		
Revenues	5.362	21.627
Other income	7.362	4.826
Total revenues and other income	12.724	26.453
Net loss	(56.419)	(972)

- As mentioned in the press release dated February 20, 2015, we draw your attention to the fact that some figures for the year ended December 31, 2013, are different from what has previously published. These corrections are explained in more details in a note which can be accessed following this link:

http://www.cellestis.com/sites/default/files/corrections_comptes_20022015_0.pdf

For further information, please contact:

Cellestis

Jennifer Moore

Phone: +33 (0)1 81 69 16 00

e-mail: media@cellectis.com



BMC Communications - New York City

Brad Miles

Phone: 646-513-3125

e-mail: bmiles@bmccommunications.com

About Collectis

Collectis is a gene-editing company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered Tcells. Collectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN™ products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Collectis' goal is to create innovative products in multiple fields and with various target markets. Collectis is listed on the NYSE Alternext market (ticker: ALCLS).

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Collectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

Consolidated Financial Position

Year Ended December 31,

	2013	2014
€ in thousands		
ASSETS		
Non-current assets		
Goodwill	1.096	-
Intangible assets	3.531	1.026
Property, plant, and equipment	3.869	2.610
Other non-current financial assets	435	1.977
Total non-current assets	8.931	5.613
Current assets		
Inventories and accumulated costs on orders in process	367	135
Trade receivables	2.687	5.881
Subsidies receivables	6.137	8.170
Other current assets	3.194	5.468
Cash and cash equivalents	7.559	112.347
Total current assets	19.944	132.001
TOTAL ASSETS	28.875	137.614
LIABILITIES		
Shareholders' equity		
Share capital	1.054	1.472
Premiums related to the share capital	133.908	192.842
Treasury share reserve	(412)	(251)
Currency translation adjustment	828	(762)
Retained earnings	(77.236)	(132.536)
Net income (loss)	(55.402)	20
Total shareholders' equity - Group Share	2.740	60.786
Non-controlling interests	(223)	(1.259)
Total shareholders' equity	2.517	59.527
Non-current liabilities		
Non-current financial debt	3.375	2.824
Non-current provisions	437	398
Total non-current liabilities	3.812	3.222
Current liabilities		
Current financial debt	691	862
Trade payables	9.700	9.802
Deferred revenues and deferred income	5.612	59.492
Redundancy plan	1.865	715
Current provisions	589	700
Other current liabilities	4.089	3.294
Total current liabilities	22.546	74.865
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	28.875	137.614



Statement of Consolidated Operations

	Year Ended December 31,	
	2013	2014
	€ in thousands	
Revenues and other income		
Revenues	5 362	21 627
Other income	7 362	4 826
Total revenues and other income	12 724	26 453
Operating expenses and other operating income (expenses)		
Royalty expenses	(542)	(3 035)
Research and development expenses	(17 844)	(14 407)
Selling, general and administrative expenses	(19 034)	(13 114)
Other operating income	478	-
Redundancy plan	(1 865)	(491)
Other operating expenses	(445)	(651)
Total operating expenses and other operating income (expenses)	(39 252)	(31 698)
Operating loss	(26 528)	(5 245)
Financial revenues	468	7 622
Financial expenses	(780)	(527)
Financial gain (loss)	(312)	7 095
Income tax	-	-
Income (loss) from continuing operations	(26 839)	1 850
Loss from discontinued operations	(29 580)	(2 822)
Net loss	(56 419)	(972)
Attributable to shareholders of Collectis	(55 402)	20
Attributable to non-controlling interests	(1 017)	(992)